Form 4 for NRXP NRX Pharmaceuticals, Inc.
Accepted 2024-12-18 00:00:00 ET · period of report 2024-12-17 · accession 0001415889-24-029694 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-18 | 2024-12-17 | NRXP | Javitt Jonathan C | COB, Chief Scientist, Dir, 10% | P - Purchase | $1.17 | +40.0K | 84.6K | +90% | +$46.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-17 | P | A | 40,000 | $1.17 | 84,634 | D | — | — |